OncoArendi Therapeutics SA (PL:MOC)
:MOC
MOC Stock Chart & Stats
zł5.20
--
Market closed
zł5.20
--
Day’s Range― - ―
52-Week Rangezł4.98 - zł9.06
Previous CloseN/A
VolumeN/A
Average Volume (3M)22.76K
Market Cap
zł140.93M
Enterprise Valuezł112.17M
Total Cash (Recent Filing)zł8.13M
Total Debt (Recent Filing)zł4.51M
Price to Earnings (P/E)―
Beta0.40
Next Earnings
Sep 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.71
Shares Outstanding24,723,785
10 Day Avg. Volume10,308
30 Day Avg. Volume22,764
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)1.54
Price to Sales (P/S)0.00
P/FCF Ratio-6.95
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.2
Revenue Forecast (FY)zł40.50M
MOC FAQ
What was OncoArendi Therapeutics SA’s price range in the past 12 months?
OncoArendi Therapeutics SA lowest stock price was zł4.98 and its highest was zł9.06 in the past 12 months.
What is OncoArendi Therapeutics SA’s market cap?
OncoArendi Therapeutics SA’s market cap is zł140.93M.
When is OncoArendi Therapeutics SA’s upcoming earnings report date?
OncoArendi Therapeutics SA’s upcoming earnings report date is Sep 30, 2026 which is in 108 days.
How were OncoArendi Therapeutics SA’s earnings last quarter?
Currently, no data Available
Is OncoArendi Therapeutics SA overvalued?
According to Wall Street analysts OncoArendi Therapeutics SA’s price is currently Overvalued.
Does OncoArendi Therapeutics SA pay dividends?
OncoArendi Therapeutics SA does not currently pay dividends.
What is OncoArendi Therapeutics SA’s EPS estimate?
OncoArendi Therapeutics SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does OncoArendi Therapeutics SA have?
OncoArendi Therapeutics SA has 24,723,785 shares outstanding.
What happened to OncoArendi Therapeutics SA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of OncoArendi Therapeutics SA?
Currently, no hedge funds are holding shares in PL:MOC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
OncoArendi Therapeutics SA
Operating as a biopharmaceutical firm in Poland, Molecure S.A. specializes in the research, development, and commercialization of innovative therapies designed to combat neoplastic (cancer) and inflammatory conditions. The company's pipeline prominently features OATD-01, a chitotriosidase/acidic mammalian chitinase inhibitor that has successfully advanced through Phase I clinical trials for the treatment of idiopathic pulmonary fibrosis and sarcoidosis. Additionally, Molecure is progressing its YKL-40 program for cancer and fibrosis, OATD-02 for oncology applications, and a Deubiquitinase program. Established in 2012, this Warsaw-headquartered enterprise adopted the name Molecure S.A. in March 2022, having previously been known as OncoArendi Therapeutics S.A.